Loading…
Falun Gong Protection Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
93pct
390d open
vs 10,564 other HR bills in the 118th — cohort avg 68d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2025 · fourth_quarter · Health Issues
S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 882: Patients Before Middlemen Act, and other legislation related to pharmacy benefit manager (PBM) reform. S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a Chance Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 2710: Open Payments Expansion Act S. 3345: PBM Price Transparency and Accountability Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Mikaela Naylon Give Kids a Chance Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 H.R. 2214: DRUG Act H.R. 3701 Family Vaccine Protection Act H.R. 4132: Prescription Information Modernization Act of 2025 H.R. 4299: Protecting Patient Access to Cancer and Complex Therapies Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 6283 Delinking Revenue from Unfair Gouging (DRUG Act) Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues MAHA Commission Report - Make Our Children Healthy Again Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues S. 5459: Biosimilars Access and Affordability Act (118th Congress) Drug shortages policy issues Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Presidential Memoranda: Memorandum for the Secretary of Health and Human Services the Commissioner of Drugs - Addressing Misleading Direct-to-Consumer Prescription Drug Advertisements
Received in the Senate and Read twice and referred to the Committee on Foreign Relations.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4134)
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4134)
DEBATE - The House proceeded with forty minutes of debate on H.R. 4132.
Considered under suspension of the rules. (consideration: CR H4133-4136)
Mr. McCormick moved to suspend the rules and pass the bill, as amended.
Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 33 - 0.
Committee Consideration and Mark-up Session Held
Referred to the Committee on Foreign Affairs, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $810,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
Introduced in House
Congress.gov source codes: 1000, Intro-H
| Referred To |
| June 14, 2023 |
| Republican |
| TX |
| Brian K. Fitzpatrick | Republican | PA |
| Burgess Owens | Republican | UT |
| George Santos | Republican | NY |
| Glenn Thompson | Republican | PA |
| Gregory F. Murphy | Republican | NC |
| Gus M. Bilirakis | Republican | FL |
| John R. Curtis | Republican | UT |
| Lance Gooden | Republican | TX |
| Maria Elvira Salazar | Republican | FL |
| Michael Lawler | Republican | NY |
| Pat Fallon | Republican | TX |
| Patrick Ryan | Democratic | NY |
| Thomas P. Tiffany | Republican | WI |
| Tim Burchett | Republican | TN |